Current status, mechanism and research progress of major sedative-hypnotic drugs for the treatment of insomnia
DOI:
https://doi.org/10.61173/rg41j705Keywords:
insomnia, sedative-hypnotics, barbiturates, benzodiazepines, novel nonbenzodiazepines, melatonin receptor agonists and melatonin analogs, orexin receptor antagonist analogsAbstract
Insomnia, a widespread condition in modern society, has seen a rise in its affected population in recent years. Prolonged insomnia not only causes anxiety and depression but also impairs individuals’ work and study efficiency while posing a threat to their physical health. Drug therapy is the predominant treatment for insomnia, encompassing drugs such as barbiturates, benzodiazepines, novel non-benzodiazepines, melatonin receptor agonists, melatonin, and orexin receptor antagonists. However, concerns arise due to the significant side effects, ease of tolerance development, dependency issues, and rebound phenomena upon drug discontinuation for some of these medications. Hence, there’s an urgent need for the research and development of novel hypnotic-sedative drugs that offer minimal toxic side effects, excellent tolerance, and reduced dependency. This paper presents a review of the mechanisms and research advancements of key sedative-hypnotic drugs in recent years. Furthermore, based on conformational relationships, we aim to predict the structure of these novel drugs, providing a valuable reference for drug research and development, while offering diverse drug options tailored to different patient needs.
References
[1] Qi Miao. Research on the clinical effect of acupuncture in the treatment of insomnia[J]. Chinese general medicine,2019,22(S1):185-187.
[2] Mellinger G D,Balter M B,Uhlenhuth E H.Insomnia and its treatment prevalence and correlates[J].Archives of General Psychiatry,1985,42(3):225- 232
[3] Xing Yixi. Current status of the application of Chinese medicine inheritance assistance platform in the treatment of insomnia by traditional Chinese medicine[J]. World Journal of Sleep Medicine,2018,5(5):558-563XING Yi-xi.
[4] ZHANG Aixin, CUI Jianqiu, YIN Fan. Survey on the Status Quo of Insomnia Population in China and Suggestions for the Development of Sleeping Aid APP Market[J]. China Market, 2021,23(1086):96-98.
[5] Liu Xiaodi, Xue Huiwen. Insomnia increases the risk of heart disease and stroke[J]. Basic Medicine and Clinics, 2020,40(4):537.
[6] ZHANG Binjia,QIU Ziliang,ZHANG Jie,. A brief history of sleep drug development[J]. World Journal of Sleep Medicine,2020(07):.
[7] Chen Z, Du JR. Pharmacology 9th edition [M]. Beijing: People’s Health Publishing House.2022:107-113.
[8] Huang ZL,Gao MP. Mechanism of action of barbiturates[J]. Foreign medicine. Synthetic drugs. Biochemical Drugs. Preparations,1983(05):15-20.
[9] You Qidong. Medicinal chemistry 8th edition [M]. Beijing: people’s health press.2016:72-83.
[10] Ke Hao Koon, Lv Sai Nan, Hao Hong Xia, Cai Neng Bin. Research progress on the detection methods of benzodiazepines[J]. Analytical Laboratory,2020 ,v.39(09):1110-1116.
[11] Zhu Aizhu. Adverse reactions and dependence of benzodiazepines[J]. Tianjin Pharmacology,1992(04):29-31.
[12] Jiang M.-S. Pharmacology. People’s Health Publishing House.1984.2 ed. 118-119.
[13] Li HF,Gu NF. A new non-benzodiazepine sedativehypnotic drug zaleplon[J]. Chinese Journal of New Drugs and Clinics,2000(06):495-498.
[14] Gunja N. The clinical and forensic toxicology of Z-drugs[J]. J Med Toxicol,2013,9(2):155-162.
[15] Xiong Nana,Luo Lei,Sun W,Fan Tenteng.Research progress on the risk of Z-drug abuse and dependence[J]. Chinese Journal of Drug Dependence,2020,29(06):401-405+429.
[16] LIU Guiping,ZHANG Guoling. Progress of research on clinical application of zolpidem[J]. China Medicine Herald,2017,14(29):41-44.
[17] Zhai Yan. Pharmacologic treatment of insomnia[J]. Huaihai medicine,2016,v.34(01):126-128.
[18] ZHOU Qihui,ZHENG Guoqing,LIN Yan. Advances in the treatment of psychiatric disorders (III):Insomnia[J]. Medicine Herald,2017,36(10):1143-1147.
[19] Zhang Shige. Research progress and clinical efficacy evaluation of melatonin receptor agonists[J]. China Hospital Drug Evaluation and Analysis,2013,13(2):112-115.
[20] Darius P Zlotos, Ralf Jockers, Erika cecon, et al. MT; and MTzmelatonin receptors: ligands, models, oligomers and therapeutoc potential. j. Med. Chem.,2014, 57 (8), 3161 -3185.
[21] HE Huajun; SHEN Xizhou; LIU Yajun; WANG Gang; GAO Ting; HU Wenxiang. Research overview of several major hypnotic drugs[C]. China People’s Public Security University Press (CPPSUP), Proceedings of the Fifth National Symposium on Chemistry in Public Safety and the Third Symposium on Hazardous Substances and Safety and Emergency Response Techniques, [China People’s Public Security University Press (CPPSUP)], 2015.276-280.
[22] Uchiyama M,Hamamura M.Kuwano T,et al.Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia[J]. Sleep Med,201l,12(2):119-126.
[23] Uehiyama M,Hanmmura M,Kuwano T. et al. Long-term safety and efficacy of rameltean in Japanese patients with chronic insomnia[J]. 12(2):127-133.
[24] Mayer G,Wang-Weigand S,Roth-Scheehter B,et al.Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia[J].Sleep,2009,32(3):351-360.
[25] Roth T, Stubbs C, Walsh JK. Ramelteon (TAK -375), a selective MT,/MT - receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. sleep, 2005,28 (3): 303 -307.
[26] Chen D, Lu V. Research progress of agomelatine in the treatment of insomnia[J]. World Clinical Drugs 2011,32(4):214- 218.
[27] STEINER M A, GATFIELD J, BRISBARE-ROCH C, et al. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type1 selective Dean&Francis antagonist[J].Chem Med Chem,2013,8(6):898-903.
[28] MAEHARA S,YUGE N,HIGASHI C,et al.Pharmacological characterization of a novel potent,selective,and or ally active orexin 2 receptor antagonist,SDM-878[J]. Neuropsychopharmacol Rep,2020,40(2):182-189.
[29] Le Viet Dan, Cui Xiaodong, Sun Yan, et al. Research progress of orexin receptor antagonist for insomnia[J]. Journal of Pharmacy, 2018,53(7):1068-1079.
[30] Norman JL,Anderson SL.Novel class of medications,orexin receptor antagonists,in the treatment of insomnia-critical appraisal of suvorexant[J ].Nat Sci Sleep,2016,8:239-247.
[31] Li Muhua,Chen Fangman,Liu Lifa,Yan Jun.Progress in the application of suvorexant in the treatment of insomnia[J]. Shandong Medicine,2020,60(08):106-109.
[32] Herring WJ,Connor KM,Ivgy-May N,et al.Suvorexant in patients with insomnia:results from two 3-month randomized controlled clinical trials[J]. Biol Psychiatry,2016,79(2):136-148.
[33] Michelson D,Snyder E,Paradis E,et al.Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation:a phase 3 randomized,doubleblind,placebo-controlled trial[J].Lancet Neurol,2014,13(5):461-471.
[34] FDA.Products on NDA 212028[EB/OL]. (2019-12-20) [2020-10-11]. https://www.accessdata.fda.gov/scripts/cder/daf/ index.cfm?event=BasicSearch.process. [ 3 5 ] S C O T T L J . L e m b o r e x a n t : f i r s t a p p r o v a l [ J ] . Drugs,2020,80(4):425-432. [ 3 6 ] M U R P H Y P, M O L I N E M , M AY L E B E N D , e t al.Lemborexant,a dual orexin receptor antagonist(DORA) for the treatment of insomnia disorder:results from a bayesian,adap tive,randomized,doubleblind,placebo-controlled study[J].J Clin Sleep Med,2017,13(11):1289-1299.
[37] Chen Shiwang,Li Yuhuan,Dong Yeqing,Sun Zhongguo. A novel anti-insomnia drug: lemborexant[J]. Chinese Journal of New Drugs and Clinics,2022,v.41(05):269-271. [ 3 8 ] WA N G Yo n g y i , H U A N G L u , J I A N G C h e n g . Daridorexant, a dual orexin receptor antagonist for the treatment of adult insomnia[J]. Chinese Journal of New Drugs,2023,v.32(07):657-661.ally active orexin 2 receptor antagonist. SDM-878[J].Neuropsychopharmacol Rep,2020,40(2):182-189.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
